Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Merck Sharp & Dohme LLC
Jong-Mu Sun; Lin Shen; Manish A Shah; Peter Enzinger; Antoine Adenis; Toshihiko Doi; Takashi Kojima; Jean-Philippe Metges; Zhigang Li; Sung-Bae Kim; Byoung Chul Cho; Wasat Mansoor; Shau-Hsuan Li; Patrapim Sunpaweravong; Maria Alsina Maqueda; Eray Goekkurt; Hiroki Hara; Luis Antunes; Christos Fountzilas; Akihito Tsuji; Victor Castro Oliden; Qi Liu; Sukrut Shah; Pooja Bhagia; Ken Kato; KEYNOTE-590 Investigators